Page 246 - 2021_04-Haematologica-web

1162
Letters to the Editor
vating splice donor mutation in the thrombopoietin gene causes
hereditary thrombocythaemia. Nat Genet. 1998;18(1):49-52.
5. Goerttler PS, Kreutz C, Donauer J, et al. Gene expression profiling in polycythaemia vera: overexpression of transcription factor NF-E2.
Br J Haematol. 2005;129(1):138-150.
6. Jutzi JS, Bogeska R, Nikoloski G, et al. MPN patients harbor recur-
rent truncating mutations in transcription factor NF-E2. J Exp Med.
2013;210(5):1003-1019.
7. Jutzi JS, Basu T, Pellmann M, et al. Altered NFE2 activity predisposes
to leukemic transformation and myelosarcoma with AML-specific
aberrations. Blood. 2019;133(16):1766-1777.
8. Kaufmann KB, Gründer A, Hadlich T, et al. A novel murine model
of myeloproliferative disorders generated by overexpression of the
transcription factor NF-E2. J Exp Med. 2012;209(1):35-50.
9. Gasiorek JJ, Blank V. Regulation and function of the NFE2 transcrip- tion factor in hematopoietic and non-hematopoietic cells. Cell Mol
Life Sci. 2015;72(12):2323-2335.
10.Shyu Y-C, Lee T-L, Ting C-Y, et al. Sumoylation of p45/NF-E2: nuclear positioning and transcriptional activation of the mammalian β-like globin gene locus. Mol Cell Biol. 2005;25(23):10365-10378.
11.Pichler A, Knipscheer P, Saitoh H, Sixma TK, Melchior F. The RanBP2 SUMO E3 ligase is neither HECT- nor RING-type. Nat Struct Mol Biol. 2004;11(10):984-991.
12. Rabellino A, Andreani C, Scaglioni PP. The role of PIAS SUMO E3- ligases in cancer. Cancer Res. 2017;77(7):1542-1547.
13.Koidl S, Eisenhardt N, Fatouros C, Droescher M, Chaugule VK, Pichler A. The SUMO2/3 specific E3 ligase ZNF451-1 regulates PML stability. Int J Biochem Cell Biol. 2016;79:478-487.
14. Motohashi H, Katsuoka F, Miyoshi C, et al. MafG sumoylation is required for active transcriptional repression. Mol Cell Biol. 2006;26(12):4652-4663.
15. Lallemand-Breitenbach V, de Thé H. PML nuclear bodies: from architecture to function. Curr Opin Cell Biol. 2018;52:154-161.
haematologica | 2021; 106(4)